HIGHLIGHTS
SUMMARY
Published: 30 January 2023 What is already known on this topic B-cell targeted therapies, in particular anti-CD20 monoclonal antibody, impair humoral response to mRNA_vaccines against SARS-CoV-2, but few data are available for anti-BAFF antibody, which is the only licensed biologic treatment for SLE. In patients exposed to Belimumab humoral response declines during the following 6 months after the second dose of mRNA_vaccines, and some patients lose cellular-mediated response to mRNA_vaccines against SARS-CoV-2 over time under Belimumab. After the third dose of mRNA_vaccines both humoral and cellular . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.